Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label, Safety And Efficacy, Two Year Extension Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Pre-Menopausal Women With Symptomatic Leiomyomata Who Have Previously Completed Study ZPU 003
ZPU-003 EXT is a 2-year extension study of ZPU-003 (NCT00882258) to determine the continued safety and efficacy of Proellex in women who have previously completed the double-blind portion of the study.
ZPU-003 EXT is a 2-year extension study of ZPU-003 (NCT00882258). The purpose of the study is to determine the continued safety and efficacy of Proellex in women who have previously completed the double-blind portion of the study. The desired primary efficacy outcome will be a changes in vaginal bleeding from baseline to 14 months and 17 months on study drug. The total duration of the study is up to 24 months including transition times, off drug intervals, and follow-up visits). It is expected that over a 16 week on drug interval menses will subside and return after a 4-8 week off drug interval (ODI).
Age
18 - 50 years
Sex
FEMALE
Healthy Volunteers
No
Women's Health Research
Phoenix, Arizona, United States
Arizona Wellness Centre for Women
Phoenix, Arizona, United States
Medical Centre for Clinical Research
San Diego, California, United States
Women's Health Care, Inc.
San Diego, California, United States
Downtown Women's Health Care
Denver, Colorado, United States
Insignia Clinical Research (Tampa Bay Women's Center)
Tampa, Florida, United States
Affiliated Clinical Research, Inc.
Las Vegas, Nevada, United States
SC Clinical Research Center
Columbia, South Carolina, United States
Advances in Health Inc.
Houston, Texas, United States
Obstetrical & Gynecolgical Associates, PA (OGA)
Houston, Texas, United States
Start Date
September 7, 2006
Primary Completion Date
October 15, 2008
Completion Date
October 15, 2008
Last Updated
June 18, 2019
65
ACTUAL participants
Proellex®
DRUG
Lead Sponsor
Repros Therapeutics Inc.
NCT07474688
NCT07137299
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06969664